

Alectinib Protocol

Indication

First line treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC).

Adjuvant treatment for adult patients with Stage IB (tumours ≥ 4 cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection

Regimen details

Day	Drug	Dose	Route
1-28	Alectinib	600mg BD	PO

Cycle frequency

Given continuously, dispense every 28 days

Number of cycles

Continuous until disease progression or unacceptable toxicity.

For adjuvant treatment, stop treatment after 2 years.

Administration

Alectinib is available as 150mg capsules. Capsules should be swallowed whole and taken with food.

If a planned dose is missed, patients should be advised to take the dose if it is more than 6 hours until the next dose is due. If it is less than 6 hours the dose should be missed. Patients should not take two doses at the same time to make up for a missed dose. If vomiting occurs after taking a dose, patients should not take an extra dose and take the next dose at the scheduled time.

Pre-medication

Nil

Emetogenicity

This regimen has mild emetic potential.

Additional supportive medication

Not routinely required.

Extravasation

N/A

Investigations – pre first cycle

Standard network pre-SACT tests + CPK

A validated ALK assay is necessary for the selection of ALK-positive NSCLC patients. ALK-positive NSCLC status must be established prior to initiation of alectinib.

Investigations – pre subsequent cycles

Investigation	Validity period
FBC	Monthly
U+Es (including creatinine)	Monthly
LFTs	Every 2 weeks for the first 3 months, monthly thereafter
CPK	Every 2 weeks for the first month, monthly or as clinically indicated thereafter
Blood pressure and heart rate	As clinically indicated

Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant

Investigation	Limit
Neutrophils	$\geq 1.0 \times 10^9/L$
Platelets	$\geq 100 \times 10^9/L$
ALT/AST	$< 3 \times ULN$
Bilirubin	$< 2 \times ULN$
CPK	$< 5 \times ULN$

Dose modifications

Management of adverse events may require dose reduction, temporary interruption, or discontinuation of treatment. The dose should be reduced in steps of 150 mg twice daily based on tolerability as per table below:

Dose level	Dose
Full dose	600mg BD
First dose reduction	450mg BD
Second dose reduction	300mg BD

Treatment should be permanently discontinued if patients are unable to tolerate the 300 mg twice daily dose.

- **Haematological toxicity**

Discuss with consultant if neutrophils $< 1.0 \times 10^9/L$ and/or platelets $< 100 \times 10^9/L$

Alectinib is not myelosuppressive. Patients may continue to take during periods of mild myelosuppression.

- **Renal impairment**

No dose adjustment is required in patients with mild or moderate renal impairment. Alectinib has not been studied in patients with severe renal impairment. However, since alectinib elimination via the kidney is negligible, no dose adjustment is required in patients with severe renal impairment.

- **Hepatic impairment**

No starting dose adjustment is required in patients with underlying mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Patients with underlying severe hepatic impairment (Child-Pugh C) should receive a starting dose of 450 mg BD. For all patients with hepatic impairment close monitoring of LFTs is recommended.

See below for management of hepatotoxicity.

- **Other toxicities**

Interstitial lung disease (ILD)/pneumonitis:

Patients should be closely monitored for pulmonary symptoms. If symptoms of ILD/pneumonitis of any grade develop, treatment should be withheld and if no other cause is identified Alectinib should be permanently discontinued.

Hepatotoxicity:

Hepatotoxicity usually occurs within the first 3 months of treatment, although can occur after this time period. If ALT/AST > 5 x ULN and bilirubin ≤ 2 x ULN: withhold treatment until recovery to ALT/AST ≤ 3 x ULN or baseline and then continue with one dose level reduction.

If ALT/AST > 3 x ULN and bilirubin > 2 times ULN: permanently discontinue treatment.

Myalgia and CPK elevation:

Patients should be advised to report any unexplained muscle pain, tenderness, or weakness.

If CPK > 5 x ULN: withhold until ≤ 2.5 x ULN or baseline and then continue with same dose.

If second occurrence or CPK > 10 x ULN: withhold until ≤ 2.5 x ULN or baseline and then continue with one dose level reduction.

Bradycardia:

Heart rate and blood pressure should be monitored as clinically indicated. Dose modification is not required in cases of asymptomatic bradycardia.

If symptomatic bradycardia (Grade 2-3): withhold until asymptomatic or heart rate ≥ 60bpm. Review concomitant medication including antihypertensives. If contributing concomitant medication identified and discontinued or dose reduced, continue with same dose on recovery. If no other cause identified continue with one dose level reduction on recovery.

If life-threatening bradycardia: Review concomitant medication including antihypertensives. If contributing concomitant medication identified and discontinued or dose reduced, continue with one dose level reduction on recovery. If no other cause identified or if recurrence permanently discontinue alectinib.

Photosensitivity:

Patients should be advised to avoid prolonged sun exposure and use broad spectrum sun screen and lip balm during treatment and for at least 7 days after discontinuation of treatment.

Adverse effects – for full details consult product literature/ reference texts**• Serious side effects**

ILD and pneumonitis

Bradycardia

Myalgia

Hepatotoxicity

• Frequently occurring side effects

Anaemia

Dysgeusia

Visual disorders

Constipation, diarrhoea

Nausea, vomiting

Stomatitis

Oedema

Weight gain

- **Other side effects**

Rash

Photosensitivity

Raised creatinine

Significant drug interactions – for full details consult product literature/ reference texts

Strong CYP3A inducers (including carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin and St. John's Wort): no dose adjustments required but close monitoring is recommended.

Strong CYP3A inhibitors (including ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole nefazodone, grapefruit or Seville oranges): no dose adjustments required but close monitoring is recommended.

P-gp substrates (including digoxin, dabigatran etexilate, topotecan, sirolimus, everolimus, nilotinib and lapatinib): potential to increase plasma level of P-gp substrate – close monitoring recommended.

BCRP substrates (including methotrexate, mitoxantrone, topotecan and lapatinib): potential to increase plasma level of BCRP substrate – close monitoring recommended.

The effectiveness of oral contraceptives may be reduced.

Use with caution with agents which may also cause bradycardia.

Additional comments

Alectinib may cause foetal harm when administered to a pregnant woman. Female patients of child-bearing potential must use highly effective contraceptive methods during treatment and for at least 3 months following the last dose.

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, a congenital lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

References

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer: <https://www.nice.org.uk/guidance/ta536>

Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta11436>

Alectinib SPC: <https://www.medicines.org.uk/emc/product/2438/smpc>

References

THIS PROTOCOL HAS BEEN DIRECTED BY DR MIRZA, CLINICIAN FOR LUNG CANCER

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

DATE October 2024

REVIEW October 2026

VERSION 3